[Thyroid hormones in metastasizing prostate cancer treated with polyestradiol phosphate].
Patients with prostate cancer demonstrate a significant change in thyroid hormones when treated with estrogens after orchiectomy. Low-dose estrogen treatment for more than six months stimulates the synthesis of thyroxine-binding globulin. As a consequence, serum level of thyroxine is also increased. Serum free thyroxine is distinctly lowered by estrogen treatment while the linear ratio of thyroxine and free thyroxine is disturbed.
D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013963:Thyroid Hormones / Q000097:blood*; D013974:Thyroxine / Q000097:blood
D045166:Estradiol Congeners; D013963:Thyroid Hormones; D004958:Estradiol; C008958:polyestradiol phosphate; D013974:Thyroxine
Schilddrüsenhormone beim metastasierenden Prostatakarzinom unter Polyoestradiolphosphat.